Benzo Nitrogen Heteroaromatic Composition for Oral Nephropathy Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions with compound 1 for treating nephropathy face issues of toxic side effects and therapeutic ineffectiveness at therapeutically effective doses.
Innovation Solution
A pharmaceutical composition comprising a therapeutically effective amount of an active ingredient A, selected from a compound represented by general formula (I) or its derivatives, in combination with a pharmaceutically acceptable excipient, formulated to achieve stable quality, high dissolution rate, good absorption, low irritation, and high bioavailability, with a content of 1.0%-90.0% and suitable excipients like microcrystalline cellulose and lactose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compound 1 is administered at therapeutically effective doses, then inhibitory activity against complement factor B is improved, but toxic side effects increase
Solution Approach 1:
The patent changes the physical and chemical parameters of compound 1 by converting it into different salt forms (trifluoroacetate, succinate, maleate salts) and crystal forms. These parameter changes modify the drug's solubility, dissolution rate, and bioavailability, enabling effective delivery at lower doses that reduce toxicity while maintaining therapeutic effectiveness against complement factor B
Solution Approach 2:
The patent creates composite pharmaceutical formulations by combining compound 1 with specific excipients including microcrystalline cellulose, lactose, and various coating materials. These composite materials improve the drug's stability, reduce irritation, and control release characteristics, allowing for safer administration at effective doses
2Ease of operation
If compound 1 is formulated for oral administration, then ease of operation is improved, but absorption and bioavailability are reduced
Solution Approach 1:
The patent modifies the chemical parameters of compound 1 by forming salts with different acidity constants and solubility characteristics. The trifluoroacetate and succinate salts specifically enhance aqueous solubility and dissolution rates, which directly improve oral absorption and bioavailability while maintaining ease of oral administration
Solution Approach 2:
The patent applies coating materials to form protective films around the pharmaceutical composition. These thin film coatings protect the compound from degradation in the gastrointestinal tract, enhance stability, and control release patterns, thereby improving bioavailability while maintaining oral administrability
3Reliability
If compound 1 is administered to achieve therapeutic effect, then inhibitory activity is improved, but irritation increases
Solution Approach 1:
The patent introduces excipients as intermediary substances that mediate between compound 1 and the biological system. These excipients include buffers, lubricants, and coating materials that reduce direct contact between the compound and mucosal tissues, thereby reducing irritation while maintaining the compound's ability to exert its therapeutic effect on complement factor B
Data Source
AI summary
A pharmaceutical composition of a benzo nitrogen heteroaromatic ring derivative and the use thereof in medicine. The pharmaceutical composition contains active ingredient A and a pharmaceutical excipient, wherein the active ingredient A is selected from a compound as represented by general formula (I) or a stereoisomer, tautomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof. The pharmaceutical composition contains 1-1000 mg of the active ingredient A, and the content of the active ingredient A is selected from 1.0-90.0%. The present invention also relates to the use of the pharmaceutical composition in the preparation of a related drug for treating nephropathy.